Practical Patient Care: April 2024 Edition Now Available… We are pleased to present your complimentary digital copy of the latest edition of Practical Patient Care. This publication provides the latest industry thinking in all areas of healthcare and is essential reading for those who want to support patients, systems, and staff. In this informative April 2024 edition, you'll find a range of insightful features, including: 🔹 Cutting-Edge Diagnostics Discover how metagenomic next-generation sequencing can help clinicians accurately diagnose patients, as well as the potential of synthetic protein switches for innovative diagnostic applications. 🔹 Optimizing Patient Outcomes Explore the latest research on the benefits of conservative oxygen therapy for patients, and gain expert insights on the use of electrical stimulation to aid wound healing. 🔹 Advancements in Wound Care Learn about recent research and development on hydrogels for effective wound care, helping to support better patient recovery and comfort. Don't miss out on this must-read edition of Practical Patient Care. Click below to access your digital copy and stay ahead of the curve in the ever-evolving healthcare landscape. https://lnkd.in/e39XTWsB Be sure to follow Practical Patient Care on LinkedIn for more industry news and insights. We would like to thank our continued supporters and team at Practical Patient Care for putting out yet another fantastic issue. We are all excited for our up and coming PPC: Diagnostic Special (to find out how you can be a part of this, contact Glen Savage to learn more [email protected] ) Bruker • Microbiology & Infection Diagnostics, Revvity, Molbio Diagnostics, Certest Biotec, S.L., EUROIMMUN, V-Veil UP Production, LIGAMED® medical Produkte GmbH, Arjo, Levabo ApS, NATROX® Wound Care , Fidia Farmaceutici SpA, Chemviron, HARTMANN GROUP, ArcticStore Pty Ltd A Division of TITAN Containers A/S, Association for Molecular Pathology (AMP), EWMA • European Wound Management Association, Association for Diagnostics & Laboratory Medicine, Zorflex James Odell, Phoebe Galbraith
Practical Patient Care
Book and Periodical Publishing
Your one stop, leading multi-platform news source for the global healthcare sector.
About us
Today’s healthcare providers are faced with the hugely challenging task of optimising medical treatment for patients, while minimising operational costs. The level of care provided plays a crucial role in health outcomes, from initial diagnosis to discharge. Technology, as in other industries, is rapidly evolving and is improving the quality of healthcare. It is not only making processes more efficient and effective for professionals and patients, but also reducing costs. Practical Patient Care is published with medical practitioners and senior managers in mind. It provides the news and information that they need to enhance healthcare delivery, improve patient outcomes, while adhering to a strict budget.
- Website
-
https://www.practical-patient-care.com/
External link for Practical Patient Care
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
Locations
-
Primary
Hatton Garden
London, GB
Employees at Practical Patient Care
-
Martin John
Sales & Marketing Director | Delivering meaningful marketing campaigns for B2B customers globally | Owner of ‘Tunnels & Tunnelling’ LinkedIn Group
-
James Odell
Senior Account Manager - Wound Care
-
Glen Savage
Specializing in empowering organizations to effectively engage and educate key industry professionals through tailored marketing strategies in the…
-
Oladimeji Ewumi
Freelance Healthcare and Life Sciences Content Marketing Writer | Biopharma, Medical AI, & Medical Devices
Updates
-
Exciting news! Qventus, Inc has launched AI Operational Assistants to revolutionize hospital operations. These innovative tools tackle administrative burdens, allowing healthcare staff to focus on patient care. By analysing real-time data, predicting needs, and taking action, these AI assistants streamline workflows, reduce inefficiencies, and enhance care delivery. Developed with leading health systems, Qventus' solution promises to boost productivity and improve patient outcomes. A game-changer for healthcare operations! https://lnkd.in/e4yJb4jF Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #HealthcareInnovation #AIinHealthcare #OperationalEfficiency
-
-
Siemens Healthineers is set to acquire the molecular imaging business of Swiss pharmaceutical company Novartis in a deal valued at over $224 million. This acquisition specifically targets the diagnostic division of Advanced Accelerator Applications (AAA), which Novartis had previously purchased in 2017 for $3.9 billion. The deal is expected to strengthen Siemens Healthineers' position in the medical imaging sector, particularly in the production of radioactive compounds crucial for PET scans used in cancer diagnosis. AAA operates Europe's second-largest network of cyclotrons, which are essential for manufacturing these radioactive materials. While Novartis is divesting the diagnostic arm of AAA, it will retain the therapeutic portion of the business, including the radiopharmaceutical Lutathera, approved for treating neuroendocrine tumors. Importantly, Siemens Healthineers will continue to partner with Novartis in the radioligand therapy (RLT) business, ensuring ongoing collaboration in this field. Novartis' decision to sell the diagnostics portion of AAA aligns with its strategy to focus on its core strengths. As a Novartis spokesperson explained, "The growth of the molecular imaging business would be best supported under the ownership of a dedicated diagnostics shareholder."The acquisition is anticipated to close by the end of 2024, subject to regulatory approvals and discussions with Novartis' works council. This move represents a significant step for Siemens Healthineers in expanding its influence in the European medical imaging market and strengthening its position in the rapidly evolving field of precision medicine. https://lnkd.in/eZ5n7iS8 Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #MedicalImaging #Acquisitions #Radiopharmaceuticals #HealthcareTechnology
-
-
Practical Patient Care is excited to present this week's LinkedIn newsletter! This edition curates the most significant stories from the past week, bringing valuable insights directly to your inbox. Enjoy! 📰 Stay informed by following Practical Patient Care on LinkedIn for the latest industry news and updates. #PracticalPatientCare
-
AISAP, an Israeli medical technology company, has received FDA 510(k) clearance for its AI-powered AISAP Cardio point-of-care ultrasound (POCUS) software platform. This cloud-based system combines four computer-assisted diagnosis modules for valvular pathologies with eight key measurements, automatically generating analyses, interpretations, and reports for cardiac ultrasound examinations. The AISAP Cardio platform is designed to enable clinicians with basic scanning skills to accurately diagnose up to 90% of common cardiac structural and functional parameters at the bedside within minutes. It provides diagnostic assessments and measurements for various cardiac parameters, including valvular pathologies, left ventricular ejection fraction, ventricular dimensions, and more. AISAP CEO Adiel Am-Shalom emphasized the platform's potential impact, stating, "AISAP Cardio was developed by top-notch technologists and cardiologists to close critical gaps in patient care. Our 'anywhere, anytime AI' approach is aimed at transforming healthcare by bringing cutting-edge diagnostic tools to the point of care." The system's performance has been validated through studies showing that non-cardiologist physicians using AISAP Cardio can interpret point-of-care echocardiograms at a level comparable to expert cardiologists. In standalone performance testing, the platform demonstrated 93% sensitivity and 93% specificity for detecting major valve diseases. This FDA clearance marks a significant step in bringing advanced AI-powered diagnostic capabilities to the point of care, potentially improving patient outcomes and healthcare efficiency across various clinical settings. https://lnkd.in/eKwUvk4w Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #MedicalAI #CardiacImaging #PointOfCareUltrasound #FDAClearance
-
-
Medtronic has reached a significant milestone with the FDA's approval of expanded magnetic resonance imaging (MRI) labeling for its deep brain stimulation (DBS) systems, including the Percept PC, Percept RC, Activa PC, RC, and SC models. This approval allows for extended active scan times, enhancing diagnostic and functional assessment options for patients. Dr. Ashwini Sharan, Chief Medical Officer of Medtronic Neuromodulation, stated, “We know that nearly 70 percent of all DBS-eligible patients are estimated to require an MRI as part of their essential care. Only Medtronic DBS systems can continue therapy ON in bipolar mode, under certain conditions, while a patient is having an MRI scan.” This unique capability ensures that patients can receive necessary imaging without interrupting their therapy. Amaza Reitmeier, Vice President and General Manager of Medtronic Brain Modulation, added, “Patients with movement disorders have debilitating tremors that often impact their ability to physically engage in everyday moments, as well as medical treatments that require stillness like an MRI. This updated labeling is another example of our unwavering commitment to enabling personalized patient care, with the goal of many more patient lives transformed with DBS therapy.” This expanded MRI labelling not only improves patient access to essential imaging but also reinforces Medtronic's leadership in providing innovative solutions for individuals with neurological disorders. https://lnkd.in/ec6ZQKGH Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #MedicalInnovation #DeepBrainStimulation #MRICompatibility #NeurologicalCare
-
-
MRIMath has achieved a significant milestone in the field of medical AI with FDA clearance for its innovative MRIMath i2Contour device and AI solution for glioblastoma (GBM) management. This cutting-edge technology aims to revolutionize the way healthcare providers handle GBM cases, offering a blend of efficiency and precision that could transform patient care. The MRIMath i2Contour device leverages advanced AI-powered tools to streamline the GBM management process, potentially saving physicians up to an hour per imaging study. This time-saving feature addresses a critical bottleneck in patient care, allowing for faster treatment initiation. The device's AI capabilities extend to accurate labeling of GBM in MRI sequences, achieving impressive accuracy rates of 95% for T1c and 92% for FLAIR images. One of the key advantages of this technology is its ability to minimize inter-user variability. The smart manual contouring feature demonstrated less than 5% variability between radiologists for T1c sequences and under 10% for FLAIR sequences. This consistency is crucial for ensuring reliable diagnoses and treatment plans across different healthcare providers and institutions. As Professor Burt Nabors from the University of Alabama's neurology department notes, "This advance in technology will help improve the outcomes for patients with glioblastoma". By providing advanced tools for rapid, longitudinal computation of segmented imaging changes, the MRIMath i2Contour device and AI solution offer a promising path forward in the challenging field of GBM management. https://lnkd.in/eZzEFX3H Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #MedicalAI #GlioblastomaTreatment #HealthcareInnovation #FDAClearance
-
-
Exciting news in healthcare innovation! BayCare Health System and Cadence are joining forces to revolutionize chronic condition management in Tampa Bay and West Central Florida. This ground-breaking partnership combines BayCare's clinical expertise with Cadence's cutting-edge technology to provide remote monitoring and virtual care for seniors. The initiative focuses on managing hypertension, congestive heart failure, and type 2 diabetes, offering real-time vital sign monitoring and 24/7 clinical support. As Cadence CEO Chris Altchek states, “Our partnership makes it possible for primary care physicians to deliver personalized, 24/7 care to all of their patients with chronic disease.” The results are impressive, with a 61% reduction in heart failure hospital readmissions and significant improvements in blood pressure and glucose levels. This initiative empowers patients to take control of their health from the comfort of their homes while receiving top-notch care. https://lnkd.in/epBC4Qis What are your thoughts on the future of remote patient monitoring? How do you see technology shaping healthcare delivery in the coming years? Share your insights below! 📰 Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #HealthcareInnovation #RemotePatientMonitoring #ChronicCare #DigitalHealth
-
-
🏥 AlgoDx gets FDA clearance for NAVOY CDS sepsis detection software AlgoDx had developed machine learning software for sepsis prediction, which is approved in the European Union (EU) and the UK. The latest regulatory milestone will enable the AI firm to enter the US market. NAVOY CDS is software as a medical device (SaMD) designed to assist clinicians in detecting sepsis in hospitalised patients, including those in the emergency department. By analysing routinely collected vital signs, the software provides early warnings of sepsis, a serious condition, enabling healthcare providers to take timely action. Read more online: https://lnkd.in/gZsfK_54 📰 Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing
-
-
MultiCare Health System is taking a significant leap forward in cancer care by implementing Azra AI's cutting-edge oncology platform. This partnership aims to revolutionize patient care and streamline operations across the entire cancer care spectrum, from initial diagnosis to survivorship. The AI-powered system analyses pathology and radiology reports in real-time, enabling rapid identification of cancer diagnoses. Care teams can reach out to newly diagnosed patients within hours rather than days or weeks, significantly reducing the chances of treatment delays. By identifying high-risk patients from screening reports, the platform minimizes the risk of missed incidental findings, ensuring timely interventions. Automation of manual tasks allows healthcare staff to focus more on patient care, enhancing the overall patient experience. John Marshall, CEO of Azra AI, emphasized the partnership's potential: “Our AI-powered platform is designed to support healthcare providers by automating critical oncology workflows, enabling earlier intervention and improved survival rates.” This collaboration between MultiCare Health System and Azra AI showcases the transformative power of AI in healthcare, promising to deliver tangible benefits to both patients and healthcare professionals in the fight against cancer. https://lnkd.in/eZc9hbiy Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #CancerCare #HealthcareInnovation #AIinHealthcare #PatientExperience
-